Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
By L. B. A. Putte, C. Atkins, M. Malaise, J. Sany, A. Russell, P. Riel, L. Settas, J. Bijlsma, S. Todesco, M. Dougados and 6 more. Annals of the Rheumatic Diseases, 2004
653 citations recorded by the source corpus.
Subfields: Hematology, Rheumatology
View Paper: https://www.semanticscholar.org/paper/6a47a2755257d8ff7c222f1c281a7bade168005a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Rheumatology
Citations in the corpus
- Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “In addition, physical function, arthritis pain, and fatigue were also improved after treatment for 24 weeks [231].”